George Fritsma

MS, MLS, Lab Scientist, Educator, Author

George Fritsma is a medical laboratory scientist, educator, and author. George contributed five chapters to Keohane EM, Butina MM, Mirza KM, Walenga JM: Rodak’s Hematology; Clinical Principles and Applications, Seventh Edition, 2025, Elsevier; and is the co-author of Bennett A, Fritsma GA, Ernst DJ: Quick Guide to Blood Collection Edition 2, 2016, Marques MB, Fritsma GA: Quick Guide to Coagulation Testing Edition 3, 2015, and Reddy V, Marques MB, Fritsma GA: Quick Guide to Hematology Testing Edition 2, 2013, along with three additional titles, all published by AACC Press. He is a consultant in the Laboratory Medicine Department of Pathology at the University of Alabama at Birmingham. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

read more

August 2025 QQ: Coagulation Control Proteins

Our August 2026 Quick Question is a simple quiz that asks, “Which is NOT an endogenous coag control protein?” This is your opportunity to review the plasma-based coagulation mechanism and recall the functions of the control proteins, available in our Educational Module entitled Coagulation Overview. One of these is NOT an endogenous control protein for […]

Comments (0)

Quick Question Archive

LinkedIn Post: FXIII Deficiency Assays

Click here for a provocative LinkedIn “Blood Doctor” post by Dr. Abdul Mannan that describes the time-honored clot solubility test and the quantitative chromogenic assay for FXIII deficiency.

Comments (0)

Factor Assays

Letter to STH: AI Models for Viscoelastic Assays

Click here for a summary of a letter to the STH editor: Yeong JK, Panigada M, Altememi MA, Favaloro EJ, Fan BE. Large language models for viscoelastic tests: a head-to-head evaluation of ChatGPT, Gemini, and DeepSeek for thromboelastography and ROTEM interpretation. Semin Thromb Hemost. 2026. doi: 10.1055/a-2918-4009. PMID: 42520817. In addition, click here for a […]

Comments (0)

Global Hemostasis Assays

Review: AI Designing the Future of Hemostasis

Check your medical library for this review article on AI-based peptide design to modify the GPIbα-VWF interaction in platelet-type von Willebrand disease: Kazmirchuk TDD, Wang J, Corbette J, et al. Designing the future of hemostasis. Semin Thromb Hemost. 2026 Jun 9. doi: 10.1055/a-2885-4368. PMID: 42225137. Abstract Bleeding disorders arising from dysfunctional platelet-protein interactions pose a […]

Comments (0)

Bleeding Disorders

August 2026 Cheat Sheet

Click the Cheat Sheet for your August 2026 edition. You can also request your personal Cheat Sheet with links to recent Fritsma Factor entries by completing the “Sign Up” entry on the right. Fritsma Factor Posts, Educational Modules, and Resources are provided compliments of Precision BioLogic, Affinity Biologicals, and George King Bio-Medical. We welcome your […]

Comments (0)

Cheat Sheets

Better Managed Anticoagulation

Click Edward Lee Carter, BSPharm BPP‘s Better Calibrated Anticoagulation LinkedIn summary from the recent ISTH meeting that describes the need for managing the risks of anticoagulant therapy through lab measurement and monitoring outcomes.

Comments (0)

Anticoagulant Therapy

July 2026 QQ Summary: VWD Therapeutic

Our July 2026 QQ asked: What VWD therapeutic is NOT a replacement factor? Our 24 participants responded… Desmopressin: 18 (75%) Humate P: 1 (4%) Vonvendi: 4 (17%) Wilate: 1 (4%) VWD bleeding is first managed by applying “PRICE:” protection, rest, ice, compression, and elevation. Next, desmopressin (DDAVP) is administered via injection, infusion, and, in Europe, […]

Comments (0)

Quick Question Archive

Emicizumab Therapy for the Newborn

Click for this Hemostasis Today column, Abdul Mannan: HAVEN 7 and the Future of Early Haemophilia Care. For a detailed follow-up to the HAVEN 7 trial, check your medical library for de Kovel M, Kenet G, Motwani J, et al; PedNet Study group. FVIII exposure, bleeding outcomes, and inhibitor development in 80 PUPs and MTPs […]

Comments (0)

Bleeding Disorders

Risk of PE in Octogenarians

Here is a provocative open-access case-control article: Lipa AJ, Janata-Schwatczek K, Sterz M, et al. Too old for PESI?: risk stratification of octogenarians with pulmonary embolism in the emergency department. Semin Thromb Hemost. 2026. doi: 10.1055/a-2896-8297. PMID: 42361814. Abstract Pulmonary embolism (PE) in octogenarians (i.e., patients >80 years) is associated with substantial morbidity and mortality, yet […]

Comments (0)

Thrombophilia

Questions or Comments?

Email George